Cargando…

Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center

BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tighe, Donal, Smith, Sinead, O'Connor, Anthony, Breslin, Niall, Ryan, Barbara, McNamara, Deirdre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/
https://www.ncbi.nlm.nih.gov/pubmed/30483525
http://dx.doi.org/10.1002/jgh3.12000
_version_ 1783366470690930688
author Tighe, Donal
Smith, Sinead
O'Connor, Anthony
Breslin, Niall
Ryan, Barbara
McNamara, Deirdre
author_facet Tighe, Donal
Smith, Sinead
O'Connor, Anthony
Breslin, Niall
Ryan, Barbara
McNamara, Deirdre
author_sort Tighe, Donal
collection PubMed
description BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at the end of induction. METHODS: This was a prospective, single‐center study. Patients were recruited from July 2015 to August 2016. Inclusion criteria were all inflammatory bowel disease patients older than 17 years who started treatment with IFX or ADL. Baseline clinical disease activity indexes were performed. Clinical response was defined as HBI ≤3 or partial Mayo score ≤4% or <30% reduction from baseline. Anti‐TNFα trough and antibody levels were measured using standard ELISA techniques. RESULTS: Thirty‐five patients were recruited, of whom 23 had Crohn's disease and 12 had ulcerative colitis. Eighteen were treated with ADL and 17 with IFX. The mean age of the cohort was 40.3 years, 62.9% were females, 34.3% were on concomitant thiopurines, and 25.7% had prior anti‐TNFα exposure. Overall response rate was 51.4%, 33.3% for ADL and 70.6% for IFX. Mean trough levels were 12.5 μg/mL for IFX and 4.4 μg/mL for ADL. There was a clear link between higher anti‐TNFα trough levels at the end of induction with clinical response rates. For IFX, mean trough level was 16.4 μg/mL for responders versus 5.3 μg/mL for non‐responders (P = 0.026). Area under the curve for association of IFX level at induction with clinical response was 0.864 (P = 0.0001). Similar link was present between higher ADL levels with clinical response, although not statistically significant. CONCLUSION: Higher trough levels at the end of induction are associated with improved response. Ongoing work will define optimal targets at this key timeframe.
format Online
Article
Text
id pubmed-6207032
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-62070322018-11-27 Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center Tighe, Donal Smith, Sinead O'Connor, Anthony Breslin, Niall Ryan, Barbara McNamara, Deirdre JGH Open Original Articles BACKGROUND AND AIM: Anti‐tumor necrosis factor alpha (TNFα) therapies have improved outcomes for patients with inflammatory bowel disease. The aim of this study was to explore the relationship between infliximab (IFX) and adalimumab (ADL) trough and antibody levels with clinical response rates at the end of induction. METHODS: This was a prospective, single‐center study. Patients were recruited from July 2015 to August 2016. Inclusion criteria were all inflammatory bowel disease patients older than 17 years who started treatment with IFX or ADL. Baseline clinical disease activity indexes were performed. Clinical response was defined as HBI ≤3 or partial Mayo score ≤4% or <30% reduction from baseline. Anti‐TNFα trough and antibody levels were measured using standard ELISA techniques. RESULTS: Thirty‐five patients were recruited, of whom 23 had Crohn's disease and 12 had ulcerative colitis. Eighteen were treated with ADL and 17 with IFX. The mean age of the cohort was 40.3 years, 62.9% were females, 34.3% were on concomitant thiopurines, and 25.7% had prior anti‐TNFα exposure. Overall response rate was 51.4%, 33.3% for ADL and 70.6% for IFX. Mean trough levels were 12.5 μg/mL for IFX and 4.4 μg/mL for ADL. There was a clear link between higher anti‐TNFα trough levels at the end of induction with clinical response rates. For IFX, mean trough level was 16.4 μg/mL for responders versus 5.3 μg/mL for non‐responders (P = 0.026). Area under the curve for association of IFX level at induction with clinical response was 0.864 (P = 0.0001). Similar link was present between higher ADL levels with clinical response, although not statistically significant. CONCLUSION: Higher trough levels at the end of induction are associated with improved response. Ongoing work will define optimal targets at this key timeframe. Wiley Publishing Asia Pty Ltd 2017-09-18 /pmc/articles/PMC6207032/ /pubmed/30483525 http://dx.doi.org/10.1002/jgh3.12000 Text en © 2017 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Tighe, Donal
Smith, Sinead
O'Connor, Anthony
Breslin, Niall
Ryan, Barbara
McNamara, Deirdre
Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title_full Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title_fullStr Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title_full_unstemmed Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title_short Positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
title_sort positive relationship between infliximab and adalimumab trough levels at completion of induction therapy with clinical response rates, at a tertiary referral center
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207032/
https://www.ncbi.nlm.nih.gov/pubmed/30483525
http://dx.doi.org/10.1002/jgh3.12000
work_keys_str_mv AT tighedonal positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter
AT smithsinead positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter
AT oconnoranthony positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter
AT breslinniall positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter
AT ryanbarbara positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter
AT mcnamaradeirdre positiverelationshipbetweeninfliximabandadalimumabtroughlevelsatcompletionofinductiontherapywithclinicalresponseratesatatertiaryreferralcenter